Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, has announced the publication of a new research study investigating the role of immune dysfunction in Parkinson's Disease $(PD)$. This study, partially funded by Coya and led by scientific advisors Dr. Aaron Thome and Dr. Stanley H. Appel, explores the correlation between inflammation, oxidative stress, and the progression of PD. Published in the journal Frontiers of Immunology, the research highlights the upregulation of pro-inflammatory cytokine transcripts such as interleukin 6 (IL-6) and interleukin 1 beta (IL-1b) in PD patients, with increased expression correlating to advanced PD stages. These findings support the dual immunomodulatory approach of Coya's investigational therapy, COYA 302, which aims to enhance regulatory T cell function and suppress inflammation. Results from this cross-sectional study have already been presented in the publication.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.